Last reviewed · How we verify
NEO212 Oral Capsule
At a glance
| Generic name | NEO212 Oral Capsule |
|---|---|
| Also known as | POH-TMZ |
| Sponsor | Neonc Technologies, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NEO212 Oral Capsule CI brief — competitive landscape report
- NEO212 Oral Capsule updates RSS · CI watch RSS
- Neonc Technologies, Inc. portfolio CI